GWAS of cerebrospinal fluid tau levels identifies risk variants for alzheimer's disease

Neuron

Volumn 78, Issue 2, 2013, Pages 256-268

  Cruchaga, Carlos ^a   Kauwe, John S K ^b   Harari, Oscar ^a   Jin, Sheng Chih ^a   Cai, Yefei ^a   Karch, Celeste M ^a   Benitez, Bruno A ^a   Jeng, Amanda T ^a   Skorupa, Tara ^a   Carrell, David ^a   Bertelsen, Sarah ^a   Bailey, Matthew ^b   McKean, David ^b   Shulman, Joshua M ^c   De Jager, Philip L ^d,e,f   Chibnik, Lori ^d,e,f   Bennett, David A ^g   Arnold, Steve E ^h   Harold, Denise ⁱ   Sims, Rebecca ⁱ   Gerrish, Amy ⁱ   Williams, Julie ⁱ   Van Deerlin, Vivianna M ^j   Lee, Virginia M Y ^j   Shaw, Leslie M ^j   Trojanowski, John Q ^j   Haines, Jonathan L ^k   Mayeux, Richard ^l   Pericak Vance, Margaret A ^m   Farrer, Lindsay A ⁿ   Schellenberg, Gerard D ^j   Peskind, Elaine R ^o,p   Galasko, Douglas ^q   Fagan, Anne M ^a   Holtzman, David M ^a   Morris, John C ^a   Goate, Alison M ^a   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM YOUNG UNIVERSITY   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^g RUSH UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ CARDIFF UNIVERSITY   (United Kingdom)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k VANDERBILT UNIVERSITY   (United States)

^l Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^m UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

ⁿ BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^p Veterans Affairs Northwest Network Mental Illness Research Education and Clinical Center   (United States)

^q UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; APOE GENE; ARTICLE; BIOINFORMATICS; CCDC50 GENE; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; CONTROLLED STUDY; ENDOPHENOTYPE; FEMALE; GEMC1 GENE; GENE; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC RISK; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; GLIS3 GENE; HUMAN; HUMAN TISSUE; IL1 RAP GENE; MAJOR CLINICAL STUDY; MALE; MAPT GENE; NEUROPATHOLOGY; NUCLEOTIDE SEQUENCE; OSTN GENE; PPAPDC2 GENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RFX3 GENE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TREM GENE; UTS2D GENE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 3; CHROMOSOMES, HUMAN, PAIR 6; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MUSCLE PROTEINS; PEPTIDE FRAGMENTS; PHENOTYPE; PHOSPHORYLATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IMMUNOLOGIC; RISK FACTORS; SERINE; TAU PROTEINS; TRANSCRIPTION FACTORS;

EID: 84876786043     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2013.02.026     Document Type: Article

References (58)

1. Accardi G., Caruso C., Colonna-Romano G., Camarda C., Monastero R., Candore G. Can Alzheimer disease be a form of type 3 diabetes?. Rejuvenation Res. 2012, 15:217-221.
2. Andersson C., Blennow K., Almkvist O., Andreasen N., Engfeldt P., Johansson S.E., Lindau M., Eriksdotter-Jonhagen M. Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiol. Aging 2007.
3. Andrews-Zwilling Y., Bien-Ly N., Xu Q., Li G., Bernardo A., Yoon S.Y., Zwilling D., Yan T.X., Chen L., Huang Y. Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J. Neurosci. 2010, 30:13707-13717.
4. Barker A., Sharp S.J., Timpson N.J., Bouatia-Naji N., Warrington N.M., Kanoni S., Beilin L.J., Brage S., Deloukas P., Evans D.M., et al. Association of genetic Loci with glucose levels in childhood and adolescence: a meta-analysis of over 6,000 children. Diabetes 2011, 60:1805-1812.
5. Bertram, L., McQueen, M., Mullin, K., Blacker, D., and Tanzi, R. (Accessed 1/26/2013). The AlzGene Database. Alzheimer Research Forum. http://www.alzgene.org.
6. Brecht W.J., Harris F.M., Chang S., Tesseur I., Yu G.Q., Xu Q., Dee Fish J., Wyss-Coray T., Buttini M., Mucke L., et al. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J. Neurosci. 2004, 24:2527-2534.
7. Buerger K., Ewers M., Pirttilä T., Zinkowski R., Alafuzoff I., Teipel S.J., DeBernardis J., Kerkman D., McCulloch C., Soininen H., Hampel H. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006, 129:3035-3041.
8. Castellano J.M., Kim J., Stewart F.R., Jiang H., DeMattos R.B., Patterson B.W., Fagan A.M., Morris J.C., Mawuenyega K.G., Cruchaga C., et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci. Transl. Med. 2011, 3:89ra57.
9. Conde L., Vaquerizas J.M., Dopazo H., Arbiza L., Reumers J., Rousseau F., Schymkowitz J., Dopazo J. PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes. Nucleic Acids Res. 2006, 34(Web Server issue):W621-W625.
10. Cruchaga C., Fernández-Seara M.A., Seijo-Martínez M., Samaranch L., Lorenzo E., Hinrichs A., Irigoyen J., Maestro C., Prieto E., Martí-Climent J.M., et al. Cortical atrophy and language network reorganization associated with a novel progranulin mutation. Cereb. Cortex 2009, 19:1751-1760.
11. Cruchaga C., Kauwe J.S., Mayo K., Spiegel N., Bertelsen S., Nowotny P., Shah A.R., Abraham R., Hollingworth P., Harold D., et al. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet. 2010, 6:e1001101.
12. Cruchaga C., Nowotny P., Kauwe J.S., Ridge P.G., Mayo K., Bertelsen S., Hinrichs A., Fagan A.M., Holtzman D.M., Morris J.C., Goate A.M. Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. Arch. Neurol. 2011, 68:1013-1019. Alzheimer's Disease Neuroimaging Initiative.
13. Cruchaga C., Kauwe J.S., Nowotny P., Bales K., Pickering E.H., Mayo K., Bertelsen S., Hinrichs A., Fagan A.M., Holtzman D.M., et al. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. Hum. Mol. Genet. 2012, 21:4558-4571. Alzheimer's Disease Neuroimaging Initiative.
14. De Jager P.L., Shulman J.M., Chibnik L.B., Keenan B.T., Raj T., Wilson R.S., Yu L., Leurgans S.E., Tran D., Aubin C., et al. A genome-wide scan for common variants affecting the rate of age-related cognitive decline. Neurobiol Aging 2012, 33:e1011-e1015.
15. de Leon M.J., DeSanti S., Zinkowski R., Mehta P.D., Pratico D., Segal S., Clark C., Kerkman D., DeBernardis J., Li J., et al. MRI and CSF studies in the early diagnosis of Alzheimer's disease. J. Intern. Med. 2004, 256:205-223.
16. Dimitri P., Warner J.T., Minton J.A., Patch A.M., Ellard S., Hattersley A.T., Barr S., Hawkes D., Wales J.K., Gregory J.W. Novel GLIS3 mutations demonstrate an extended multisystem phenotype. Eur. J. Endocrinol. 2011, 164:437-443.
17. Dubé M.P., Schmidt S., Hauser E., Darabi H., Li J., Barhdadi A., Wang X., Sha Q., Zhang Z., Wang T., et al. Multistage designs in the genomic era: providing balance in complex disease studies. Genet. Epidemiol. 2007, 31(Suppl 1):S118-S123.
18. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 2006, 59:512-519.
19. Farías G., Cornejo A., Jiménez J., Guzmán L., Maccioni R.B. Mechanisms of tau self-aggregation and neurotoxicity. Curr. Alzheimer Res. 2011, 8:608-614.
20. Gibb G.M., Pearce J., Betts J.C., Lovestone S., Hoffmann M.M., Maerz W., Blackstock W.P., Anderton B.H. Differential effects of apolipoprotein E isoforms on phosphorylation at specific sites on tau by glycogen synthase kinase-3 beta identified by nano-electrospray mass spectrometry. FEBS Lett. 2000, 485:99-103.
21. Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J.S., Younkin S., et al. TREM2 Variants in Alzheimer's Disease. N Engl J Med. 2012.
22. Hampel H., Buerger K., Zinkowski R., Teipel S.J., Goernitz A., Andreasen N., Sjoegren M., DeBernardis J., Kerkman D., Ishiguro K., et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch. Gen. Psychiatry 2004, 61:95-102.
23. Han M.R., Schellenberg G.D., Wang L.S. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study. BMC Neurol. 2010, 10:90. Alzheimer's Disease Neuroimaging Initiative.
24. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
25. Holmans P., Green E.K., Pahwa J.S., Ferreira M.A., Purcell S.M., Sklar P., Owen M.J., O'Donovan M.C., Craddock N. Gene ontology analysis of GWA study data sets provides insights into the biology of bipolar disorder. Am. J. Hum. Genet. 2009, 85:13-24. Wellcome Trust Case-Control Consortium.
26. Hu W.T., Trojanowski J.Q., Shaw L.M. Biomarkers in frontotemporal lobar degenerations-progress and challenges. Prog. Neurobiol. 2011, 95:636-648.
27. Jagust W.J., Landau S.M., Shaw L.M., Trojanowski J.Q., Koeppe R.A., Reiman E.M., Foster N.L., Petersen R.C., Weiner M.W., Price J.C., Mathis C.A. Relationships between biomarkers in aging and dementia. Neurology 2009, 73:1193-1199. Alzheimer's Disease Neuroimaging Initiative.
28. Jia J.P., Meng R., Sun Y.X., Sun W.J., Ji X.M., Jia L.F. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. Neurosci. Lett. 2005, 383:12-16.
29. Jones L., Holmans P.A., Hamshere M.L., Harold D., Moskvina V., Ivanov D., Pocklington A., Abraham R., Hollingworth P., Sims R., et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS ONE 2010, 5:e13950.
30. Kauwe J.S., Jacquart S., Chakraverty S., Wang J., Mayo K., Fagan A.M., Holtzman D.M., Morris J.C., Goate A.M. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann. Neurol. 2007, 61:446-453.
31. Kauwe J.S., Cruchaga C., Mayo K., Fenoglio C., Bertelsen S., Nowotny P., Galimberti D., Scarpini E., Morris J.C., Fagan A.M., et al. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc. Natl. Acad. Sci. USA 2008, 105:8050-8054.
32. Kauwe J.S., Wang J., Mayo K., Morris J.C., Fagan A.M., Holtzman D.M., Goate A.M. Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics 2009, 10:13-17.
33. Kauwe J.S., Cruchaga C., Bertelsen S., Mayo K., Latu W., Nowotny P., Hinrichs A.L., Fagan A.M., Holtzman D.M., Goate A.M. Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels. J. Alzheimers Dis. 2010, 21:833-842. Alzheimer's Disease Neuroimaging Initiative.
34. Kauwe J.S., Cruchaga C., Karch C.M., Sadler B., Lee M., Mayo K., Latu W., Su'a M., Fagan A.M., Holtzman D.M., et al. Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease. PLoS ONE 2011, 6:e15918. Alzheimer's Disease Neuroimaging Initiative.
35. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 2001, 21:372-381.
36. Keenan B.T., Shulman J.M., Chibnik L.B., Raj T., Tran D., Sabuncu M.R., Allen A.N., Corneveaux J.J., Hardy J.A., Huentelman M.J., et al. A coding variant in CR1 interacts with APOE-ε4 to influence cognitive decline. Hum. Mol. Genet. 2012, 21:2377-2388. Alzheimer's Disease Neuroimaging Initiative.
37. Kim S., Swaminathan S., Shen L., Risacher S.L., Nho K., Foroud T., Shaw L.M., Trojanowski J.Q., Potkin S.G., Huentelman M.J., et al. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 2011, 76:69-79. Alzheimer's Disease Neuroimaging Initiative.
38. Koch W., Ehrenhaft A., Griesser K., Pfeufer A., Müller J., Schömig A., Kastrati A. TaqMan systems for genotyping of disease-related polymorphisms present in the gene encoding apolipoprotein E. Clin. Chem. Lab. Med. 2002, 40:1123-1131.
39. Kraft P., Cox D.G. Study designs for genome-wide association studies. Adv. Genet. 2008, 60:465-504.
40. Marcus J.N., Schachter J. Targeting post-translational modifications on tau as a therapeutic strategy for Alzheimer's disease. J. Neurogenet. 2011, 25:127-133.
41. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
42. Myers A.J., Gibbs J.R., Webster J.A., Rohrer K., Zhao A., Marlowe L., Kaleem M., Leung D., Bryden L., Nath P., et al. A survey of genetic human cortical gene expression. Nat. Genet. 2007, 39:1494-1499.
43. Naj A.C., Jun G., Beecham G.W., Wang L.S., Vardarajan B.N., Buros J., Gallins P.J., Buxbaum J.D., Jarvik G.P., Crane P.K., et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat. Genet. 2011, 43:436-441.
44. Price J.L., Morris J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol. 1999, 45:358-368.
45. Price A.L., Patterson N.J., Plenge R.M., Weinblatt M.E., Shadick N.A., Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 2006, 38:904-909.
46. Ringman J.M., Younkin S.G., Pratico D., Seltzer W., Cole G.M., Geschwind D.H., Rodriguez-Agudelo Y., Schaffer B., Fein J., Sokolow S., et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 2008, 71:85-92.
47. Rohlfs R.V., Taylor C., Mirea L., Bull S.B., Corey M., Anderson A.D. One-stage design is empirically more powerful than two-stage design for family-based genome-wide association studies. BMC Proc 2007, 1(Suppl 1):S137.
48. Schneider J.A., Aggarwal N.T., Barnes L., Boyle P., Bennett D.A. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J. Alzheimers Dis. 2009, 18:691-701.
49. Schoonenboom N.S., Mulder C., Van Kamp G.J., Mehta S.P., Scheltens P., Blankenstein M.A., Mehta P.D. Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same?. Ann. Neurol. 2005, 58:139-142.
50. Shoji M., Matsubara E., Kanai M., Watanabe M., Nakamura T., Tomidokoro Y., Shizuka M., Wakabayashi K., Igeta Y., Ikeda Y., et al. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease. J. Neurol. Sci. 1998, 158:134-140.
51. Strozyk D., Blennow K., White L.R., Launer L.J. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003, 60:652-656.
52. Sunderland T., Linker G., Mirza N., Putnam K.T., Friedman D.L., Kimmel L.H., Bergeson J., Manetti G.J., Zimmermann M., Tang B., et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003, 289:2094-2103.
53. Webster J.A., Gibbs J.R., Clarke J., Ray M., Zhang W., Holmans P., Rohrer K., Zhao A., Marlowe L., Kaleem M., et al. Genetic control of human brain transcript expression in Alzheimer disease. Am. J. Hum. Genet. 2009, 84:445-458. NACC-Neuropathology Group.
54. Welge V., Fiege O., Lewczuk P., Mollenhauer B., Esselmann H., Klafki H.W., Wolf S., Trenkwalder C., Otto M., Kornhuber J., et al. Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J. Neural Transm. 2009, 116:203-212.
55. Yang J., Manolio T.A., Pasquale L.R., Boerwinkle E., Caporaso N., Cunningham J.M., de Andrade M., Feenstra B., Feingold E., Hayes M.G., et al. Genome partitioning of genetic variation for complex traits using common SNPs. Nat. Genet. 2011, 43:519-525.
56. Yoshida T., Shiroshima T., Lee S.J., Yasumura M., Uemura T., Chen X., Iwakura Y., Mishina M. Interleukin-1 receptor accessory protein organizes neuronal synaptogenesis as a cell adhesion molecule. J. Neurosci. 2012, 32:2588-2600.
57. Zhou J., Chen J., Feng Y. Effect of truncated-ApoE4 overexpression on tau phosphorylation in cultured N2a cells. Journal of Huazhong University of Science and Technology, Medical Sciences 2006, 26:272-274.
58. Zou F., Chai H.S., Younkin C.S., Allen M., Crook J., Pankratz V.S., Carrasquillo M.M., Rowley C.N., Nair A.A., Middha S., et al. Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants. PLoS Genet. 2012, 8:e1002707. Alzheimer's Disease Genetics Consortium.